Center for Psychiatry and Behavioral Medicine, Inc., 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV 89128, USA.
Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):373-392. doi: 10.1016/j.chc.2022.03.001. Epub 2022 May 11.
Stimulants have been available for the treatment of attention-deficit/hyperactivity disorder (ADHD) for more than 70 years and are the most effective medications available. During the past 2 decades, several new immediate-release (IR) and extended-release methylphenidate (MPH) and amphetamine (AMPH) formulations have become available. These products differ by dose form (capsules, tablets, oral suspensions, oral disintegrating tablets, and patch), by onset and duration of effect, and by bioavailability. The side effect profile is generally similar for all compounds. Although the products are similar, individual patients may have a better response or tolerability to a particular class (MPH or AMPH) or formulation.
兴奋剂已经被用于治疗注意力缺陷多动障碍(ADHD)超过 70 年,是最有效的药物。在过去的 20 年中,有几种新的即时释放(IR)和缓释哌甲酯(MPH)和苯丙胺(AMPH)制剂已经上市。这些产品在剂型(胶囊、片剂、口服混悬剂、口腔崩解片和贴剂)、起效时间和作用持续时间以及生物利用度方面存在差异。所有化合物的副作用谱通常相似。虽然这些产品相似,但个别患者可能对特定类别(MPH 或 AMPH)或制剂有更好的反应或耐受性。